Lack of Effect of Beta-blocker Therapy in Patients with ST-elevation Acute Myocardial Infarction in PCI Era
|
|
- Gilbert Smith
- 6 years ago
- Views:
Transcription
1 Lack of Effect of Beta-blocker Therapy in Patients with ST-elevation Acute Myocardial Infarction in PCI Era B. Bao 1, N. Ozasa 1, T. Morimoto 2, Y. Furukawa 3, M. Shirotani 4, H. Ogawa 5, C. Tei 6, H. Fujiwara 7, K. Mitsudo 8, T. Kimura 1, on behalf of CREDO-Kyoto Registry Cohort2 investigators (1) Kyoto University Graduate School of Medicine, Department of Cardiovascular Medicine, Kyoto, Japan (2) Kyoto University Hospital, Kyoto, Japan (3) Kobe City Medical Center General Hospital, Kobe, Japan (4) Nara of Department of Medicine at Kinki University Hospital, Nara, Japan (5) Kumamoto University Hospital, Kumamoto, Japan (6) Kagoshima University, Kagoshima, Japan (7) Hyogo Prefectural Amagasaki Hospital, Amagasaki, Japan (8) Kurashiki Central Hospital, Cardiology Department, Kurashiki, Japan
2 Disclosures Nothing to disclosure
3 Background Beta-blocker therapy for patients with ST-elevation acute myocardial infarction (STEMI) is recommended by clinical guidelines. Class I 1. Patients receiving beta-blockers within the first 24 hours of STEMI without adverse effects should continue to receive them during the early convalescent phase of STEMI. (Level of Evidence: A) 2. Patients without contraindications to beta-blockers who did not receive them within the first 24 hours after STEMI should have them started in the early convalescent phase. (Level of Evidence: A) Antman EM, et al. Circulation. 2004;110(9):e However, the effect of beta blockers in STEMI patients who have undergone percutaneous coronary intervention (PCI) has not been adequately evaluated.
4 Beta Blocker Therapy was not Associated with Better 3-year Clinical Outcomes in J-Cypher Registry Ozasa N, et al. Am J Cardiol. 2010;106(9):
5 Beta Blocker Therapy was not Associated with Better 3-year Clinical Outcomes in J-Cypher Registry Ozasa N, et al. Am J Cardiol. 2010;106(9):
6 Methods
7 Study Patients The Coronary REvascularization Demonstrating Outcome Study in Kyoto (CREDO-Kyoto) AMI registry is a physician-initiated non-company sponsored multicenter registry enrolling consecutive AMI patients undergoing coronary revascularization within 7 days after the onset in 26 tertiary hospitals in Japan. Among 5429 patients enrolled in the CREDO-Kyoto AMI registry, we identified 3692 patients who have undergone PCI within 24 hours after the onset of STEMI and survived the index hospitalization.
8 Statistics The primary outcome measure for the current analyses was a composite endpoint of cardiac death and recurrent MI (cardiac death/mi). Cumulative incidences of clinical event rates were estimated by the Kaplan-Meier method. Multivariable Cox proportional-hazards model was developed by using beta-blocker therapy and 39 clinically relevant factors and then stratified by centers to estimate the hazard ratios (HR) of beta-blockers. Subgroup analyses were performed in patients with the preserved left ventricular ejection fraction (LVEF) and low LVEF.
9 Results
10 Study Flowchart median follow-up duration: 955 days; inter-quartile range: days
11 Baseline Clinical Characteristics Age (years) Age >=75 years Male BMI BMI <25.0 Onset-to-balloon time (hours) Onset-to-balloon times 6 hours Door-to-balloon time (hours) Anterior infarction Killip classification I II III IV Hypertension Diabetes mellitus on insulin therapy Current smoking beta group N = ± (26%) 1255 (78%) 23.5 ( ) 1105 (69%) 2.4 ( ) 987 (70%) 1.5 ( ) 850 (53%) 1247 (77%) 133 (8%) 37 (2%) 197 (12%) 1384 (86%) 494 (31%) 58 (4%) 687 (43%) no-beta group N = ± (32%) 1498 (72%) 23.3 ( ) 1531 (74%) 2.7 ( ) 1237 (67%) 1.5 ( ) 955 (46%) 1642 (79%) 168 (8%) 45 (2%) 223 (11%) 1519 (73%) 669 (32%) 93 (4%) 849 (41%) p value
12 Baseline Clinical Characteristics Heart failure Shock at presentation Multivessel disease MR grade 3/4 LVEF LVEF 40% Prior myocardial infarction Prior Stroke Peripheral vascular disease egfr <30, not on dialysis Dialysis Atrial fibrillation Anemia (Hb <11.0g/dl) Platelet <100*109/l COPD Liver cirrhosis Malignancy (Continue) beta group N= (28%) 234 (15%) 814 (50%) 38 (2%) 52.4± (17%) 139 (9%) 164 (10%) 42 (3%) 51 (3%) 25 (2%) 163 (10%) 135 (8%) 28 (2%) 31 (2%) 44 (3%) 118 (7%) no-beta group N= (27%) 271 (13%) 1048 (50%) 53 (3%) 54.3± (14%) 178 (9%) 235 (11%) 80 (4%) 71 (3%) 22 (1%) 171 (8%) 171 (8%) 27 (1%) 93 (4%) 46 (2%) 175 (8%) p value
13 Baseline Procedural Characteristics DES use Number of target lesions Target of proximal LAD Target of unprotected LMC Target of CTO Target of bifurcation Side-branch stenting Total number of stents Total stent length (mm) Total stent >28mm Minimum stent size (mm) Minimum stent size <3.0mm beta group N= (30%) 1 (1-2) 947 (59%) 42 (3%) 51 (3%) 413 (26%) 45 (3%) 1 (1-2) 25 (18-43) 661 (44%) 3 ( ) 479 (32%) no-beta group N= (30%) 1 (1-1) 1057 (51%) 49 (2%) 58 (3%) 532 (26%) 62 (3%) 1 (1-2) 24 (18-42) 799 (42%) 3 ( ) 584 (31%) p value
14 Baseline Medication Antiplatelet therapy Thienopyridine Ticlopidine Clopidogrel Aspirin Cilostazol Other medication Statins ACE-I/ARB Nitrates Calcium channel blockers Nicorandil Warfarin Proton pump inhibitors H2-blockers beta group N= (97%) 1424 (91%) 140 (9%) 1607 (99.6%) 541 (34%) 1033 (64%) 1339 (83%) 421 (26%) 333 (21%) 487 (30%) 237 (15%) 587 (36%) 533 (33%) no-beta group N= (96%) 1837 (92%) 159 (8%) 2063 (99.3%) 770 (37%) 1054 (51%) 1452 (70%) 695 (33%) 431 (21%) 599 (29%) 190 (9%) 695 (33%) 777 (37%) p value
15 Crude and Adjusted Cumulative Incidence Curves for Cardiac Death/MI among Patients Treated with or without Beta Blockers in the Entire Cohort
16 Crude and Adjusted Cumulative Incidence Curves for Cardiac Death/MI among Patients Treated with or without Beta Blockers in the Preserved-LVEF subgroup
17 Crude and Adjusted Cumulative Incidence Curves for Cardiac Death/MI among Patients Treated with or without Beta Blockers in the Low-LVEF subgroup
18 Discussions
19 Most of STEMI patients treated with PCI had preserved LVEF and the cardiac event rates after hospital discharge were relatively low. Beta-blocker prescription at discharge was not associated with better clinical outcomes but rather it was associated with worse 3-year cardiovascular outcomes. Trends for worse outcomes in the beta group were consistently seen regardless of LVEF.
20 Compare to Other Registry the Event Rates were Relatively Low Unadjusted 1-year mortality for patients prescribed beta blocker or not beta group no-beta group p value Cooperative Cardiovascular Project* Nonrevascularization Group 15.4% 29.4% <0.001 Cooperative Cardiovascular Project PTCA Group 4.6% 7.5% <0.001 CREDO-Kyoto AMI registry 3.5% 4.0% 0.18 *The Cooperative Cardiovascular Project (CCP) is a nationwide quality improvement project (quality indicator measurement, feedback, remeasurement) in Medicare AMI patients sponsored by the Health Care Financing Administration. In Maine, New Hampshire, and Vermont, 3,472 baseline records were abstracted from 76 hospitals from January 1994 to February Chen J, et al. Arch Intern Med. 2000;160(7):
21 The Mechanism of the Effects of Beta Blockers in Patients with STEMI Attenuation of the myocardial oxygen demand by decreases in heart rate, blood pressure, and myocardial contractility via an adenosine-dependent mechanism. Asanuma H, et al. Circulation 2004;109: Beta blockers are also thought to be effective in reducing tachyarrhythmic events. Vitale C, et al. Angiology. 2010;61(8): However, the adverse effects of beta blockers such as hypotension, bradycardia, dizziness, depression, drug allergy, and metabolic disorders might overwhelm the benefit of beta blockers in STEMI patients who have undergone PCI and have no residual ischemia. Freemantle N, et al. Br Med J. 1999;318(7200):
22 Limitations We do not know whether the participants continued beta blockers after discharge. The current study did not have adequate power to assess outcomes in this small subgroup with low LVEF. Selection bias for use of beta blockers is inevitable in this type of observational study.
23 Conclusions In this large observational cohort study, oral beta-blocker therapy was associated with worse 3-year clinical outcomes in patients with STEMI who have undergone PCI. Large-scale randomized controlled trials are needed to evaluate the role of beta-blocker therapy in STEMI patients who have undergone PCI.
24 Acknowledgement Kyoto University Hospital Kishiwada City Hospital Tenri Hospital Hyogo Prefectural Amagasaki Hospital Kitano Hospital Koto Memorial Hospital Kokura Memorial Hospital Maizuru Kyosai Hospital Nara Hospital, Kinki University Faculty of Medicine Kobe City Medical Center General Hospital Nishi-Kobe Medical Center Kansai Denryoku Hospital Osaka Red Cross Hospital University of Fukui Hospital Shizuoka City Shizuoka Hospital Hamamatsu Rosai Hospital Shiga University of Medical Science Hospital Japanese Red Cross Wakayama Medical Center Shimabara Hospital Kagoshima University Medica and Dental Hospital Shizuoka General Hospital Kurashiki Central Hospital Mitsubishi Kyoto Hospital Kumamoto University Hospital Shimada Municipal Hospital Juntendo University Shizuoka Hospital
Comparison of Three-year Outcome after PCI and CABG in Triple Vessel Coronary Artery Disease. CREDO-Kyoto PCI/CABG Registry Cohort-2
Comparison of Three-year Outcome after PCI and CABG in Triple Vessel Coronary Artery Disease Stratified analysis by the SYNTAX Score CREDO-Kyoto PCI/CABG Registry Cohort-2 Hiroki Shiomi, Junichi Tazaki,
More informationhttps://dx.doi.org/ /doctor.
β-blocker therapy and cardiovascula Titlewho have undergone percutaneous cor ST-elevation myocardial infarction( Author(s) Bao, Bingyuan Citation Kyoto University ( 京都大学 ) Issue Date 2014-03-24 URL https://dx.doi.org/10.14989/doctor.
More informationBeta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes
Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes Seung-Jae Joo and other KAMIR-NIH investigators Department of Cardiology, Jeju National
More informationPrediction of Thrombotic and Bleeding Events After Percutaneous Coronary Intervention: CREDO-Kyoto Thrombotic and Bleeding Risk Scores
ORIGINAL RESEARCH Prediction of Thrombotic and Bleeding Events After Percutaneous Coronary Intervention: CREDO-Kyoto Thrombotic and Bleeding Risk Scores Masahiro Natsuaki, MD; Takeshi Morimoto, MD; Kyohei
More informationSupplementary Material to Mayer et al. A comparative cohort study on personalised
Suppl. Table : Baseline characteristics of the patients. Characteristic Modified cohort Non-modified cohort P value (n=00) Age years 68. ±. 69.5 ±. 0. Female sex no. (%) 60 (0.0) 88 (.7) 0.0 Body Mass
More informationEffect of upstream clopidogrel treatment in patients with ST-segment elevation myocardial infarction undergoing primary PCI
Effect of upstream clopidogrel treatment in patients with ST-segment elevation myocardial infarction undergoing primary PCI Dr Sasha Koul, MD Dept of Cardiology, Lund University Hospital, Lund, Sweden
More information10-Year Mortality of Older Acute Myocardial Infarction Patients Treated in U.S. Community Practice
10-Year Mortality of Older Acute Myocardial Infarction Patients Treated in U.S. Community Practice Ajar Kochar, MD on behalf of: Anita Y. Chen, Puza P. Sharma, Neha J. Pagidipati, Gregg C. Fonarow, Patricia
More informationThe MAIN-COMPARE Study
Long-Term Outcomes of Coronary Stent Implantation versus Bypass Surgery for the Treatment of Unprotected Left Main Coronary Artery Disease Revascularization for Unprotected Left MAIN Coronary Artery Stenosis:
More informationPROMUS Element Experience In AMC
Promus Element Luncheon Symposium: PROMUS Element Experience In AMC Jung-Min Ahn, MD. University of Ulsan College of Medicine, Heart Institute, Asan Medical Center, Seoul, Korea PROMUS Element Clinical
More informationORIGINAL ARTICLE. Ischemic Heart Disease
Circulation Journal Official Journal of the Japanese Circulation Society http://www.j-circ.or.jp ORIGINAL ARTICLE Ischemic Heart Disease Distinct Survival Benefits of Angiotensin-Converting Enzyme Inhibitors/Angiotensin
More informationHypothesis: When compared to conventional balloon angioplasty, cryoplasty post-dilation decreases the risk of SFA nses in-stent restenosis
Cryoplasty or Conventional Balloon Post-dilation of Nitinol Stents For Revascularization of Peripheral Arterial Segments Background: Diabetes mellitus is associated with increased risk of in-stent restenosis
More informationUNmasking Dormant Electrical Reconduction by Adenosine TriPhosphate
KPAF trial The Kansai Plus Atrial Fibrillation (KPAF) trial is a 2x2 factorial randomized controlled trial, composed of the UNDER-ATP and EAST-AF trials. Efficacy of adenosine triphosphate guided ablation
More informationBern-Rotterdam Cohort Study
Bern-Rotterdam Cohort Study Newer generation everolimus-eluting stents eliminate the risk of very late stent thrombosis compared with early generation sirolimus-eluting and paclitaxel-eluting stents Lorenz
More informationWhat is the Optimal Triple Anti-platelet Therapy Duration in Patients with Acute Myocardial Infarction Undergoing Drug-eluting Stents Implantation?
What is the Optimal Triple Anti-platelet Therapy Duration in Patients with Acute Myocardial Infarction Undergoing Drug-eluting Stents Implantation? Keun-Ho Park, Myung Ho Jeong, Min Goo Lee, Jum Suk Ko,
More informationAbstract Background: Methods: Results: Conclusions:
Two-Year Clinical and Angiographic Outcomes of Overlapping Sirolimusversus Paclitaxel- Eluting Stents in the Treatment of Diffuse Long Coronary Lesions Kang-Yin Chen 1,2, Seung-Woon Rha 1, Yong-Jian Li
More informationIschemic Heart Disease Interventional Treatment
Ischemic Heart Disease Interventional Treatment Cardiac Catheterization Laboratory Procedures (N = 11,61) is a regional and national referral center for percutaneous coronary intervention (PCI). A total
More information4. Which survey program does your facility use to get your program designated by the state?
STEMI SURVEY Please complete one survey for each TCD designation you have in your facility. There would be a maximum of three surveys completed if your facility was designated as a trauma, stroke and STEMI
More informationFinal Clinical and Angiographic Results From a Nationwide Registry of FIREBIRD Sirolimus- Eluting Stent: Firebird In China (FIC) Registry (PI R. Gao)
The Microport FIREBIRD Polymer-based Sirolimus- Eluting Stent Clinical Trial Program Update: The FIC and FIREMAN Registries Junbo Ge, MD, FACC, FESC, FSCAI On behalf of Runlin Gao (FIC PI) and Haichang
More informationComparison of Percutaneous Coronary Intervention With Coronary Artery Bypass Grafting in Unprotected Left Main Coronary Artery Disease
1282 SHIOMI H et al. Circulation Journal ORIGINAL ARTICLE Official Journal of the Japanese Circulation Society http://www.j-circ.or.jp Cardiovascular Intervention Comparison of Percutaneous Coronary Intervention
More information1. Diabetes mellitus (DM) is associated with worse clinical and angiographic outcomes even in acute myocardial Infarction (AMI) patients.
Midterm Clinical Outcomes of Insulin Requiring Diabetes Mellitus versus Non-insulin Dependent Diabetes Mellitus in Acute Myocardial Infarction Patients in Drug Eluting Stent Era : Insight from Korea Acute
More informationDiabetic Patients: Current Evidence of Revascularization
Diabetic Patients: Current Evidence of Revascularization Alexandra J. Lansky, MD Yale University School of Medicine University College of London The Problem with Diabetic Patients Endothelial dysfunction
More informationWhat oral antiplatelet therapy would you choose? a) ASA alone b) ASA + Clopidogrel c) ASA + Prasugrel d) ASA + Ticagrelor
76 year old female Prior Hypertension, Hyperlipidemia, Smoking On Hydrochlorothiazide, Atorvastatin New onset chest discomfort; 2 episodes in past 24 hours Heart rate 122/min; BP 170/92 mm Hg, Killip Class
More informationControversies in Cardiac Pharmacology
Controversies in Cardiac Pharmacology Thomas D. Conley, MD FACC FSCAI Disclosures I have no relevant relationships with commercial interests to disclose. 1 Doc, do I really need to take all these medicines?
More informationPerspectives From the CREDO-Kyoto Registry Cohort-2
Circulation Journal Official Journal of the Japanese Circulation Society http://www.j-circ.or.jp ORIGINAL ARTICLE Cardiovascular Intervention Intensity of Statin Therapy, Achieved Low-Density Lipoprotein
More informationBelinda Green, Cardiologist, SDHB, 2016
Acute Coronary syndromes All STEMI ALL Non STEMI Unstable angina Belinda Green, Cardiologist, SDHB, 2016 Thrombus in proximal LAD Underlying pathophysiology Be very afraid for your patient Wellens
More informationIschemic Heart Disease Interventional Treatment
Ischemic Heart Disease Interventional Treatment Cardiac Catheterization Laboratory Procedures (N = 89) is a regional and national referral center for percutaneous coronary intervention (PCI). A total of
More informationProgram Metrics. New Unique ID. Old Unique ID. Metric Set Metric Name Description. Old Metric Name
Program Metrics The list below includes the metrics that will be calculated by the PINNACLE Registry for the outpatient office setting. These include metrics for, Atrial Fibrillation, Hypertension and.
More informationGALECTIN-3 PREDICTS LONG TERM CARDIOVASCULAR DEATH IN HIGH-RISK CORONARY ARTERY DISEASE PATIENTS
GALECTIN-3 PREDICTS LONG TERM CARDIOVASCULAR DEATH IN HIGH-RISK CORONARY ARTERY DISEASE PATIENTS Table of Contents List of authors pag 2 Supplemental figure I pag 3 Supplemental figure II pag 4 Supplemental
More informationSubsequent management and therapies
ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation Subsequent management and therapies Marco Valgimigli, MD, PhD University of Ferrara ITALY
More informationDECISION-CTO. Optimal Medical Therapy With or Without Stenting For Coronary Chronic Total Occlusion. Seung-Jung Park, MD., PhD.
DECISION-CTO Optimal Medical Therapy With or Without Stenting For Coronary Chronic Total Occlusion Seung-Jung Park, MD., PhD. Heart Institute, University of Ulsan College of Medicine Asan Medical Center,
More informationDECLARATION OF CONFLICT OF INTEREST
DECLARATION OF CONFLICT OF INTEREST Is there a mortality risk associated with aspirin use in heart failure? Results from a large community based cohort Margaret Bermingham, Mary-Kate Shanahan, Saki Miwa,
More informationAsian AMI Registry Session The 17 th Joint Meeting of Coronary Revascularization (JCR 2017) Busan, Korea Dec 8 th 2017
Asian AMI Registry Session The 17 th Joint Meeting of Coronary Revascularization (JCR 2017) Busan, Korea Dec 8 th 2017 Trends of acute myocardial infarction in Korea from the experience of Korea Acute
More informationRelationship between body mass index, coronary disease extension and clinical outcomes in patients with acute coronary syndrome
Relationship between body mass index, coronary disease extension and clinical outcomes in patients with acute coronary syndrome Helder Dores, Luís Bronze Carvalho, Ingrid Rosário, Sílvio Leal, Maria João
More informationManagement of Stable Ischemic Heart Disease. Vinay Madan MD February 10, 2018
Management of Stable Ischemic Heart Disease Vinay Madan MD February 10, 2018 1 Disclosure No financial disclosure. 2 Overview of SIHD Diagnosis Outline of talk Functional vs. Anatomic assessment Management
More informationBifurcation stenting with BVS
Bifurcation stenting with BVS Breaking the limits or just breaking the struts? Maciej Lesiak Department of Cardiology University Hospital in Poznan, Poland Disclosure Speaker s name: Maciej Lesiak I have
More informationThe MAIN-COMPARE Registry
Long-Term Outcomes of Coronary Stent Implantation versus Bypass Surgery for the Treatment of Unprotected Left Main Coronary Artery Disease Revascularization for Unprotected Left MAIN Coronary Artery Stenosis:
More informationSHOULD BETA BLOCKERS BE USED ROUTINELY IN POST MI PATIENTS WITH PRESERVED LV FUNCTION?
SHOULD BETA BLOCKERS BE USED ROUTINELY IN POST MI PATIENTS WITH PRESERVED LV FUNCTION? Doron Zahger, MD Department of Cardiology, Soroka University Medical Center, Faculty of Health Sciences, Ben Gurion
More informationSupplementary Table S1: Proportion of missing values presents in the original dataset
Supplementary Table S1: Proportion of missing values presents in the original dataset Variable Included (%) Missing (%) Age 89067 (100.0) 0 (0.0) Gender 89067 (100.0) 0 (0.0) Smoking status 80706 (90.6)
More informationDavid E. Kandzari, MD Director, Interventional Cardiology Research Scripps Clinic La Jolla, California
38 RCTs 18,000 pts Identifying the Optimal Duration of DAPT Less is More, More or Less David E. Kandzari, MD Director, Interventional Cardiology Research Scripps Clinic La Jolla, California kandzari.david@scrippshealth.org
More informationPatient characteristics Intervention Comparison Length of followup
ISCHAEMIA TESTING CHAPTER TESTING FOR MYCOCARDIAL ISCHAEMIA VERSUS NOT TESTING FOR MYOCARDIAL ISCHAEMIA Ref ID: 4154 Reference Wienbergen H, Kai GA, Schiele R et al. Actual clinical practice exercise ing
More informationQuality Payment Program: Cardiology Specialty Measure Set
Quality Payment Program: Cardiology Specialty Set Title Number CMS Reporting Method(s) Heart Failure (HF): Angiotensin- Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for
More informationAlex versus Xience Registry Preliminary report
Interventional Cardiology Network Alex versus Xience Preliminary report Mariusz Gąsior 1,2, Marek Gierlotka 1, Lech Poloński 1,2 1 3rd Department of Cardiology, Medical University of Silesia Centre tor
More informationTransfer in D2B. Scott D Friedman, MD FACC Medical Director, Cardiology Services Shore Health System of Maryland. The Problem
Transfer in D2B Scott D Friedman, MD FACC Medical Director, Cardiology Services Shore Health System of Maryland The Problem NRMI-5: North Carolina, July 2003- June 2004 NC Nation Guidelines N 2,738 79,927
More informationHyeon-Cheol Gwon, On the behalf of SMART-DATE trial investigators ACC LBCT 2018
Six-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndromes (SMART-DATE): a randomized, openlabel, multicenter trial
More informationSUPPLEMENTAL MATERIAL
SUPPLEMENTAL MATERIAL 1 Supplemental Table 1. ICD codes Diagnoses, surgical procedures, and pharmacotherapy used for defining the study population, comorbidity, and outcomes Study population Atrial fibrillation
More informationTransient Atrial Fibrillation and Risk of Stroke after Acute Myocardial Infarction
Transient Atrial Fibrillation and Risk of Stroke after Acute Myocardial Infarction Doron Aronson MD, Gregory Telman MD, Fadel BahouthMD, Jonathan Lessick MD, DSc and Rema Bishara MD Department of Cardiology
More informationThe University of Mississippi School of Pharmacy
LONG TERM PERSISTENCE WITH ACEI/ARB THERAPY AFTER ACUTE MYOCARDIAL INFARCTION: AN ANALYSIS OF THE 2006-2007 MEDICARE 5% NATIONAL SAMPLE DATA Lokhandwala T. MS, Yang Y. PhD, Thumula V. MS, Bentley J.P.
More information1. Whether the risks of stent thrombosis (ST) and major adverse cardiovascular and cerebrovascular events (MACCE) differ from BMS and DES
1 Comparison of Ischemic and Bleeding Events After Drug- Eluting Stents or Bare Metal Stents in Subjects Receiving Dual Antiplatelet Therapy: Results from the Randomized Dual Antiplatelet Therapy (DAPT)
More informationHospital and 1-year outcome after acute myocardial infarction in patients with diabetes mellitus and hypertension
(2003) 17, 665 670 & 2003 Nature Publishing Group All rights reserved 0950-9240/03 $25.00 www.nature.com/jhh ORIGINAL ARTICLE Hospital and 1-year outcome after acute myocardial infarction in patients with
More informationPractice-Level Executive Summary Report
PINNACLE Registry Metrics 0003, Test Practice_NextGen [Rolling: 1st April 2015 to 31st March 2016 ] Generated on 5/11/2016 11:37:35 AM American College of Cardiology Foundation National Cardiovascular
More informationSUPPLEMENTAL MATERIAL
SUPPLEMENTAL MATERIAL Table S1: Number and percentage of patients by age category Distribution of age Age
More informationTCTAP Upendra Kaul MD,DM,FACC,FSCAI,FAMS,FCSI
Indian TUXEDO Trial In Medically Treated Diabetics Upendra Kaul MD,DM,FACC,FSCAI,FAMS,FCSI Executive Director and Dean Escorts Heart Institute & Medical Research Center and Fortis Hospitals, New Delhi
More informationJournal of the American College of Cardiology Vol. 46, No. 8, by the American College of Cardiology Foundation ISSN /05/$30.
Journal of the American College of Cardiology Vol. 46, No. 8, 2005 2005 by the American College of Cardiology Foundation ISSN 0735-1097/05/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2005.06.070
More informationShould All Patients Be Treated with Ace-inh /ARB after STEMI with Preserved LV Function?
Should All Patients Be Treated with Ace-inh /ARB after STEMI with Preserved LV Function? Avi Shimony, MD, FESC Cardiology Division Soroka University Medical Center Ben-Gurion University, Beer-Sheva Disclosure
More informationQuality Payment Program: Cardiology Specialty Measure Set
Measure Title * Reportable via PINNACLE α Reportable via Diabetes Collaborative CQMC v1.0 Measure High Priority Measure Cross Cutting Measure Heart Failure (HF): Angiotensin- Converting Enzyme (ACE) Inhibitor
More informationDECLARATION OF CONFLICT OF INTEREST
DECLARATION OF CONFLICT OF INTEREST How to manage antiplatelet treatment in patients with diabetes in acute coronary syndrome Lars Wallentin Professor of Cardiology, Chief Researcher Cardiovascular Science
More informationRevascularization after Drug-Eluting Stent Implantation or Coronary Artery Bypass Surgery for Multivessel Coronary Disease
Impact of Angiographic Complete Revascularization after Drug-Eluting Stent Implantation or Coronary Artery Bypass Surgery for Multivessel Coronary Disease Young-Hak Kim, Duk-Woo Park, Jong-Young Lee, Won-Jang
More informationUnprotected Left Main Coronary Artery Disease in Patients With Low Predictive Risk of Mortality
Unprotected Left Main Coronary Artery Disease in Patients With Low Predictive Risk of Mortality Shun Watanabe, MD, Tatsuhiko Komiya, MD, Genichi Sakaguchi, MD, PhD, and Takeshi Shimamoto, MD, PhD Department
More informationCardiovascular Health Practice Guideline Outpatient Management of Coronary Artery Disease 2003
Authorized By: Medical Management Guideline Committee Approval Date: 12/13/01 Revision Date: 12/11/03 Beta-Blockers Nitrates Calcium Channel Blockers MEDICATIONS Indicated in post-mi, unstable angina,
More informationOptimal Duration and Dose of Antiplatelet Therapy after PCI
Optimal Duration and Dose of Antiplatelet Therapy after PCI Donghoon Choi, MD, PhD Severance Cardiovascular Center Yonsei University College of Medicine Optimal Duration of Antiplatelet Therapy after PCI
More informationISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions
Julinda Mehilli, MD Deutsches Herzzentrum Technische Universität Munich Germany ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions Background Left main
More informationRole of Clopidogrel in Acute Coronary Syndromes. Hossam Kandil,, MD. Professor of Cardiology Cairo University
Role of Clopidogrel in Acute Coronary Syndromes Hossam Kandil,, MD Professor of Cardiology Cairo University ACS Treatment Strategies Reperfusion/Revascularization Therapy Thrombolysis PCI (with/ without
More informationKnow the Quality of our Care at Every Step. Kansas City ACS Summit BI-State Cardiovascular Education Consortium
Know the Quality of our Care at Every Step Kansas City ACS Summit BI-State Cardiovascular Education Consortium Welcome to the Kansas City ACS Summit Objectives: Follow the flow and care of an ACS patient
More informationEffect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial
Effect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial Myeong-Ki Hong, MD. PhD on behalf of the IVUS-XPL trial investigators
More informationJoo-Yong Hahn, MD/PhD
Sungkyunkwan University School of Medicine Joo-Yong Hahn, MD/PhD Heart Vascular Stork Institute, Samsung Medical Center Sungkyunkwan University School of Medicine Grant support Korean Society of Interventional
More informationUnprotected LM intervention
Unprotected LM intervention Guideline for COMBAT Seung-Jung Park, MD, PhD Professor of Internal Medicine, Seoul, Korea Current Recommendation for unprotected LMCA Stenosis Class IIb C in ESC guideline
More informationTreatment Options for Angina
Treatment Options for Angina Interventional Cardiology Perspective Michael A. Robertson, M.D. 10/30/10 Prevalence of CAD in USA 15 million Americans with CAD 2 million diagnostic catheterizations 1 million
More informationStent Thrombosis Importance of Pharmacotherapy
Stent Thrombosis Importance of Pharmacotherapy George D. Dangas, MD, FSCAI Columbia University Medical Center Cardiovascular Research Foundation New York City SCAI-2007 Orlando, FL Presenter Disclosure
More information(ClinicalTrials.gov ID: NCT ) Title: The Italian Elderly ACS Study Author: Stefano Savonitto. Date: 29 August 2011 Meeting: ESC congress, Paris
Early aggressive versus initially conservative strategy in elderly patients with non-st- elevation acute coronary syndrome: the Italian randomised trial (ClinicalTrials.gov ID: NCT00510185) Stefano Savonitto,
More informationGRAND ROUNDS - DILEMMAS IN ANTICOAGULATION AND ANTIPLATELET THERAPY. Nick Collins February 2017
GRAND ROUNDS - DILEMMAS IN ANTICOAGULATION AND ANTIPLATELET THERAPY Nick Collins February 2017 DISCLOSURES Before I commence Acknowledge.. Interventional Cardiologist Perception evolved. Interventional
More informationProton Pump Inhibitors increase Cardiovascular risk in patient taking Clopidogrel
Proton Pump Inhibitors increase Cardiovascular risk in patient taking Clopidogrel Dr.A.K.M. Aminul Hoque Assoc. Prof. of Medicine. Dhaka Medical College. Clopidogrel Metabolism Clopidogrel is an inactive
More informationThe ESC Registry on Chronic Ischemic Coronary Disease
EURObservational Research Programme The ESC Registry on Chronic Ischemic Coronary Disease Prof. Fausto J. Pinto, FESC, FACC, FASE, FSCAI Immediate Past-President, ESC University Hospital Sta Maria University
More information3-year results of the OLIVE registry:
3-year results of the OLIVE registry: A prospective multicenter study in patients with critical limb ischemia Osamu Iida, MD Kansai Rosai Hospital Cardiovascular Center Amagasaki, Hyogo, Japan Disclosure
More informationAre Asian Patients Different? - Updates Of Biomatrix Experience In Regional Settings: BEACON II (3 Yr F up) &
Are Asian Patients Different? - Updates Of Biomatrix Experience In Regional Settings: BEACON II (3 Yr F up) & Biomatrix TM Single Center Experience (Indonesia)(Final 5 Yr F up) T. Santoso University of
More informationSTEMI update. Vijay Krishnamoorthy M.D. Interventional Cardiology
STEMI update Vijay Krishnamoorthy M.D. Interventional Cardiology OVERVIEW Current Standard of Care in Management of STEMI Update in management of STEMI Pre-Cath Lab In the ED/Office/EMS. Cath Lab Post
More informationAcute Myocardial Infarction. Willis E. Godin D.O., FACC
Acute Myocardial Infarction Willis E. Godin D.O., FACC Acute Myocardial Infarction Definition: Decreased delivery of oxygen and nutrients to the myocardium Myocardial tissue necrosis causing irreparable
More informationCurrent Advances and Best Practices in Acute STEMI Management A pharmacoinvasive approach
Current Advances and Best Practices in Acute STEMI Management A pharmacoinvasive approach Frans Van de Werf, MD, PhD University Hospitals, Leuven, Belgium Frans Van de Werf: Disclosures Research grants
More informationRationale for Prophylactic Support During Percutaneous Coronary Intervention
Rationale for Prophylactic Support During Percutaneous Coronary Intervention Navin K. Kapur, MD, FACC, FSCAI Assistant Director, Interventional Cardiology Director, Interventional Research Laboratories
More informationSupplementary Online Content
1 Supplementary Online Content Friedman DJ, Piccini JP, Wang T, et al. Association between left atrial appendage occlusion and readmission for thromboembolism among patients with atrial fibrillation undergoing
More informationA Multicenter Randomized Trial of Immediate Versus Delayed Invasive Strategy in Patients with Non-ST Elevation ACS
Angioplasty to Blunt the rise Of troponin in Acute coronary syndromes Randomized for an immediate or Delayed intervention A Multicenter Randomized Trial of Immediate Versus Delayed Invasive Strategy in
More informationDual Antiplatelet Therapy Made Practical
Dual Antiplatelet Therapy Made Practical David Parra, Pharm.D., FCCP, BCPS Clinical Pharmacy Program Manager in Cardiology/Anticoagulation VISN 8 Pharmacy Benefits Management Clinical Associate Professor
More informationLM stenting - Cypher
LM stenting - Cypher Left main stenting with BMS Since 1995 Issues in BMS era AMC Restenosis and TLR (%) 3 27 TLR P=.282 Restenosis P=.71 28 2 1 15 12 Ostium 5 4 Shaft Bifurcation Left main stenting with
More informationCover Page. The handle holds various files of this Leiden University dissertation
Cover Page The handle http://hdl.handle.net/1887/21543 holds various files of this Leiden University dissertation Author: Dharma, Surya Title: Perspectives in the treatment of cardiovascular disease :
More informationStent Thrombosis in Coronary Bifurcation After DES Implantation
Welcome to the 5 th European Bifurcation Club 16-17 September 2009 - BERLIN Stent Thrombosis in Coronary Bifurcation After DES Implantation Insight From J-Cypher Registry and Asian Multicenter Registry
More informationSafety of Single- Versus Multi-vessel Angioplasty for Patients with AMI and Multi-vessel CAD
Safety of Single- Versus Multi-vessel Angioplasty for Patients with AMI and Multi-vessel CAD Mun K. Hong, MD Associate Professor of Medicine Director, Cardiovascular Intervention and Research Weill Cornell
More informationΔιάρκεια διπλής αντιαιμοπεταλιακής αγωγής. Νικόλαος Γ.Πατσουράκος Καρδιολόγος, Επιμελητής Α ΕΣΥ Τζάνειο Γενικό Νοσοκομείο Πειραιά
Διάρκεια διπλής αντιαιμοπεταλιακής αγωγής Νικόλαος Γ.Πατσουράκος Καρδιολόγος, Επιμελητής Α ΕΣΥ Τζάνειο Γενικό Νοσοκομείο Πειραιά International ACS guidelines: Recommendations on duration of dual
More informationOlive registry: 3-years outcome of BTK intervention in Japan. Osamu Iida, MD Kansai Rosai Hospital Amagasaki, Hyogo, Japan
Olive registry: 3-years outcome of BTK intervention in Japan Osamu Iida, MD Kansai Rosai Hospital Amagasaki, Hyogo, Japan What is the optimal treatment for the patient with critical limb ischemia (CLI)?
More informationDownloaded from:
Annemans, L; Danchin, N; Van de Werf, F; Pocock, S; Licour, M; Medina, J; Bueno, H (2016) Prehospital and in-hospital use of healthcare resources in patients surviving acute coronary syndromes: an analysis
More informationDECISION - CTO. optimal Medical Treatment in patients with. Seung-Jung Park, MD, PhD, FACC for the DECISION-CTO Study investigators
DECISION - CTO Drug-Eluting stent Implantation versus optimal Medical Treatment in patients with ChronIc Total OccluSION Seung-Jung Park, MD, PhD, FACC for the DECISION-CTO Study investigators Asan Medical
More informationOptimal Duration of Clopidogrel Therapy with DES to Reduce Late Coronary Arterial Thrombotic Event. The DES LATE Trial
Optimal Duration of Clopidogrel Therapy with DES to Reduce Late Coronary Arterial Thrombotic Event The DES LATE Trial Cheol Whan Lee, MD, Seung-Jung Park, MD, PhD, On Behalf of the DES LATE Investigators
More informationDownloaded from by on September 30, 2018
Incidence and Outcome of Surgical Procedures After Coronary Bare-Metal and Drug-Eluting Stent Implantation A Report From the CREDO-Kyoto PCI/CABG Registry Cohort-2 Akihiro Tokushige, MD*; Hiroki Shiomi,
More informationDisclosures. Dr. Scirica has also served as a consultant for Lexicon, Arena, Gilead, and Eisai.
Disclosures Benjamin M. Scirica, MD, MPH, is employed by the TIMI Study Group, which has received research grants from Abbott, AstraZeneca, Amgen, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb,
More informationUpdate interventional Cardiology Hans Rickli St.Gallen
Update interventional Cardiology 2012 Hans Rickli St.Gallen 26.11.2012 Review of Literature ESC-Highlights TCT/AHA-Highlights Update interventional cardiology 2012 Structural Heart Disease Transcatheter
More informationCan Angiographic Complete Revascularization Improve Outcomes for Patients with Decreased LV Function? NO!
Can Angiographic Complete Revascularization Improve Outcomes for Patients with Decreased LV Function? NO! Young-Hak Kim, MD, PhD Heart Institute, University of Ulsan College of Medicine Asan Medical Center,
More informationA Randomized Comparison of Clopidogrel and Aspirin Versus Ticlopidine and Aspirin After the Placement of Coronary Artery Stents
Journal of the American College of Cardiology Vol. 41, No. 6, 2003 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00 Published by Elsevier Science Inc. doi:10.1016/s0735-1097(02)02974-1
More informationCoronary Revascularization in Patients With Liver Cirrhosis
Coronary Revascularization in Patients With Liver Cirrhosis Akira Marui, MD, PhD, Takeshi Kimura, MD, PhD, Shiro Tanaka, PhD, Senri Miwa, MD, PhD, Kazuhiro Yamazaki, MD, PhD, Kenji Minakata, MD, PhD, Tomohiro
More informationCoronary Artery Disease: Revascularization (Teacher s Guide)
Stephanie Chan, M.D. Updated 3/15/13 2008-2013, SCVMC (40 minutes) I. Objectives Coronary Artery Disease: Revascularization (Teacher s Guide) To review the evidence on whether percutaneous coronary intervention
More informationTicagrelor compared with clopidogrel in patients with acute coronary syndromes the PLATO trial
compared with clopidogrel in patients with acute coronary syndromes the PLATO trial August 30, 2009 at 08.00 CET PLATO background In NSTE-ACS and STEMI, current guidelines recommend 12 months aspirin and
More informationClinical Seminar. Which Diabetic Patient is a Candidate for Percutaneous Coronary Intervention - European Perspective
Clinical Seminar Which Diabetic Patient is a Candidate for Percutaneous Coronary Intervention - European Perspective Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical
More informationIs bypass surgery needed for elderly patients with LMT disease? From the surgical point of view
CCT 2003 (Kobe) Is bypass surgery needed for elderly patients with LMT disease? From the surgical point of view Hitoshi Yaku, MD, PhD Department of Cardiovascular Surgery Kyoto Prefectural University of
More information